Kane Biotech to Release First Quarter 2022 Financial Results on May 26 – Conference Call to Follow
Kane Biotech Inc. (OTCQB: KNBIF) will release its first quarter 2022 financial results after market close on May 26, 2022. The announcement will be followed by a conference call at 4:30 p.m. ET to discuss the results and related business developments. Kane Biotech specializes in technologies aimed at preventing and removing microbial biofilms, and holds a diverse portfolio, including 81 patents. For further information, the management team will provide a live broadcast and replay accessible on their website.
- None.
- Reliance on equity and external financing due to lack of significant revenues to date.
- Early-stage development may hinder market acceptance of products.
- Risks related to intellectual property protection and dependence on strategic partners.
WINNIPEG, Manitoba, May 19, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2022 financial results after market close on Thursday, May 26, 2022.
Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
| First Quarter 2022 Results Conference Call Details: | |
| Date: | Thursday May 26, 2022 |
| Time: | 4:30 p.m. ET |
| Live Call: | 1-877-268-9044 (Canada and the United States) 1-706-679-2995 (International) |
| Replay: | 1-404-537-3406 |
| Conference ID: | 8674975 |
| Webcast URL: | https://edge.media-server.com/mmc/p/sp8wmtiw |
The call will also be broadcast live and archived on the Company's website at www.kanebiotech.com under "News/Events" in the Investors section.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (81 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
| For more information: | ||
| Marc Edwards | Ray Dupuis | Nicole Sendey |
| Chief Executive Officer | Chief Financial Officer | Investor Relations/PR |
| Kane Biotech Inc | Kane Biotech Inc | Kane Biotech Inc |
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | nsendey@kanebiotech.com |
| +1 (514) 910-6991 | +1 (204) 298-2200 | +1 (250) 327-8675 |
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
When will Kane Biotech announce its Q1 2022 financial results?
What time is Kane Biotech's conference call for Q1 2022 results?
What is the main focus of Kane Biotech's business?
What is the stock symbol for Kane Biotech?
How can I access the conference call replay for Kane Biotech?
